Alectinib

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Retrieved on: 
Monday, April 8, 2024
EGFR, Patient, Anaplastic lymphoma kinase, Research, Alectinib, Active ingredient, Lung cancer, AACR, AstraZeneca, ALK, Vaccine

Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.

Key Points: 
  • The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.
  • In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase (ALK)-resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells.
  • Alectinib is the active ingredient in AlecensaTM, an ALK inhibitor approved for the treatment of NSCLC.
  • Moreover, effective inhibition of signaling pathways associated with osimertinib and alectinib resistance were observed in the respective cell lines tested.

Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer

Retrieved on: 
Friday, September 1, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, ALINA, European Medicines Agency, Cancer, Light, Roche, Medicine, NSCLC, Alectinib, Lung cancer, Rated R, ROG, EMA, RO, NCCN, Journal of the National Comprehensive Cancer Network, Patient, Risk, Anaplastic lymphoma kinase, Phase, Recurrence, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DFS, Food, Biopsy, Disease, ALK, Pharmaceutical industry, Genentech

Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected Stage IB (tumor ≥ 4 cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Key Points: 
  • Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected Stage IB (tumor ≥ 4 cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
  • Alecensa is the first and only ALK inhibitor to demonstrate a reduction in the risk of disease recurrence or death for people with early-stage ALK-positive NSCLC in a Phase III trial.
  • “If approved, Alecensa has the potential to treat cancer before it has spread in a setting where treatment can increase the chances of cure, which is our ultimate goal at Genentech.
  • ALK-positive NSCLC is often found in younger people – usually 55 and under – who have a light or non-smoking history.

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research

Retrieved on: 
Monday, May 29, 2023
Smoker, Atezolizumab, Complex conjugate, Lung cancer, Tobacco, Alectinib, Cough, Hospital, Acquisition, Patient, Investment, EGFR, Diffuse large B-cell lymphoma, Risk, Eli Lilly and Company, Spacecraft, Health, Air pollution, Virus, Disease, ALK, Therapy, Crizotinib, Entrectinib, Research, Paclitaxel, Boehringer Ingelheim, ARIAD Pharmaceuticals, Growth, Pembrolizumab, Smoking, Erlotinib, Docetaxel, Gas, Cancer, Osimertinib, Chest pain, Traction, Blood, Immune system, ROS1, Trastuzumab emtansine, Teva Pharmaceuticals, Radiation, Pfizer, Bristol Myers Squibb, AstraZeneca, Lung, Novartis, Smoke, Nivolumab, Pharmaceutical industry, Renewable energy, Vaccine, Bayer, Genentech, Talimogene laherparepvec

With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.

Key Points: 
  • With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.
  • The business intelligence report on Lung Cancer Therapies Market by Brandessence Market Research is curated with an aim to provide the industry participants with a succulent overview of this industry.
  • By treatment, the chemotherapy segment is projected to amass notable gains due to its efficacy in treating lung cancer.
  • The Lung Cancer Therapies Market is anticipated to garner significant returns over the estimated timeline of 2022-2029.

Research Report on China's Alectinib Markets, 2016-2020 & 2021-2025: Originally Developed by Roche for Patients with the Zotinib-Resistant ALK-Positive Non-Small Cell Lung Cancer - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Oncology, Roche, Research report, CSCO, EML4-ALK positive lung cancer, Category, Risk, Marketing, ESMO, The Different Company, Insurance, FDA, China Energy Research Report, Pollution, Dosage form, Lung cancer, NCCN, Nominal interest rate, HIV disease progression rates, Occupational Safety and Health Act 1994, Patient, COVID-19, Death, Capsule, CAGR, Income, NSCLC, Animal, Pharmaceutical industry, Health insurance, Alectinib

The "Research Report on China's Alectinib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Alectinib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Alectinib, originally developed by Roche, was first approved by the FDA on December 11, 2015, for patients with the zotinib-resistant ALK-positive non-small cell lung cancer.
  • On November 6, 2017, the FDA also approved alectinib as a first-line agent for ALK-positive patients.
  • However, for most Chinese patients, the monthly expenditure of approximately CNY15,230 (USD2,340) on alectinib is still too high.

OptimizeRx Survey Addresses Treatment Selection, Discontinuation and Switching in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer – an Indication with Limited Patient Population

Retrieved on: 
Wednesday, December 15, 2021
Organization, Forward-looking statement, Food, FDA, AE, HIV disease progression rates, Physician, Drug Quality and Security Act, Securities Exchange Act of 1934, Regulation, Time, Securities Act of 1933, ALK, Oncology, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Disease, GLOBE, NSCLC, Alectinib, Compliance, Large-cell lung carcinoma, Pharmaceutical industry

The survey explores affordability dynamics, pharmaceutical manufacturers support, challenges faced by patients in staying on therapy, and reasons why patients may switch or discontinue treatment.

Key Points: 
  • The survey explores affordability dynamics, pharmaceutical manufacturers support, challenges faced by patients in staying on therapy, and reasons why patients may switch or discontinue treatment.
  • Many ALK+ NSCLC patients switch or discontinue treatment for reasons other than lack of efficacy and disease progression including adverse events, cost, or poor medication compliance.
  • This strongly suggests that better patient support with managing the effects and costs of their treatment could significantly reduce the number of patients who stop or switch treatment.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer

Retrieved on: 
Thursday, October 14, 2021
Large-cell lung carcinoma, Amgen, Pharma, Industry, Eli Lilly and Company, Turning Point, Entrectinib, Lists of people executed in the United States, Classification, Daiichi Sankyo, Novartis, Roche, Sanofi, Merck Group, Intelligence, ADC, Brigatinib, NSCLC, Pralsetinib, Medtech, Blueprint, Osimertinib, Chemoradiotherapy, KOL, Research, Turning Point Alcohol and Drug Centre, Alectinib, Mirati, AstraZeneca, Pharmaceutical industry, Fine chemical

A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.

Key Points: 
  • A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
  • In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
  • How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
  • Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?

Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

Retrieved on: 
Tuesday, September 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., REPARE THERAPEUTICS’ SNIPRX® PLATFORM, REPARE THERAPEUTICS, INC.

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman.
  • It is my pleasure to welcome Tom to our Board as our new Chairman, said Repare President and CEO Lloyd M. Segal.
  • I am delighted to join Repare and other members of the Board during this exciting time for the Company, said Mr. Civik.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

Retrieved on: 
Tuesday, March 9, 2021
Chemical compounds, Chemistry, Organic compounds, Piperidines, Breakthrough therapy, Protein kinase inhibitors, Ceritinib, Tyrosine kinase receptors, Crizotinib, Alectinib, Anaplastic lymphoma kinase, Lorlatinib

The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.

Key Points: 
  • The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.
  • "It is essential that we identify patients with this cancer biomarker quickly and accurately so they can be treated with effective targeted therapy.
  • The VENTANA ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted treatments - XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) and LORBRENA (lorlatinib).
  • It is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) or LORBRENA (lorlatinib) in the US.

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

Retrieved on: 
Tuesday, March 9, 2021
Chemical compounds, Chemistry, Organic compounds, Piperidines, Breakthrough therapy, Protein kinase inhibitors, Ceritinib, Tyrosine kinase receptors, Crizotinib, Alectinib, Anaplastic lymphoma kinase, Lorlatinib

The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.

Key Points: 
  • The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.
  • "It is essential that we identify patients with this cancer biomarker quickly and accurately so they can be treated with effective targeted therapy.
  • The VENTANA ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted treatments - XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) and LORBRENA (lorlatinib).
  • It is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) or LORBRENA (lorlatinib) in the US.

Kanazawa University research: Potential combined drug therapy for lung cancer

Retrieved on: 
Thursday, January 21, 2021
Clinical medicine, Branches of biology, Chemical compounds, Non-small-cell lung carcinoma, Lung cancer, Small-cell carcinoma, Alectinib, Anaplastic lymphoma kinase, Cancer, Carcinoma, Treatment of lung cancer, Targeted therapy of lung cancer

KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable.

Key Points: 
  • KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable.
  • This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment.
  • Non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two types of lung cancer.
  • However, in certain scenarios where gene alterations occur, the drug has an adverse effect, as now shown by Azusa Tanimoto from Kanazawa University and colleagues.